Ad
CNCE Quote Trading Chart Concert Pharmaceuticals Inc.
home / stock / cnce / cnce quote
Quote | Concert Pharmaceuticals Inc. (NASDAQ:CNCE)
| Last: | $8.37 |
|---|---|
| Change Percent: | -0.12% |
| Open: | $8.38 |
| Close: | $8.37 |
| High: | $8.55 |
| Low: | $8.35 |
| Volume: | 10,733,298 |
| Last Trade Date Time: | 03/03/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
CNCE Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $8.37 | $8.38 | $8.37 | $8.55 | $8.35 | 10,733,298 | 03-03-2023 |
| $8.36 | $8.39 | $8.36 | $8.39 | $8.345 | 4,637,577 | 03-02-2023 |
| $8.39 | $8.37 | $8.39 | $8.39 | $8.37 | 2,169,805 | 03-01-2023 |
| $8.38 | $8.38 | $8.38 | $8.4 | $8.38 | 1,022,876 | 02-28-2023 |
| $8.4 | $8.39 | $8.4 | $8.41 | $8.38 | 1,701,244 | 02-27-2023 |
| $8.38 | $8.39 | $8.38 | $8.4 | $8.375 | 824,692 | 02-24-2023 |
| $8.39 | $8.39 | $8.39 | $8.405 | $8.39 | 1,337,003 | 02-23-2023 |
| $8.4 | $8.38 | $8.4 | $8.41 | $8.37 | 876,045 | 02-22-2023 |
| $8.35 | $8.38 | $8.35 | $8.41 | $8.34 | 1,846,216 | 02-21-2023 |
| $8.38 | $8.38 | $8.38 | $8.44 | $8.37 | 735,479 | 02-20-2023 |
| $8.38 | $8.38 | $8.38 | $8.44 | $8.37 | 735,479 | 02-17-2023 |
| $8.38 | $8.35 | $8.38 | $8.41 | $8.345 | 1,561,765 | 02-16-2023 |
| $8.35 | $8.36 | $8.35 | $8.3862 | $8.33 | 1,187,358 | 02-15-2023 |
| $8.34 | $8.33 | $8.34 | $8.36 | $8.32 | 1,577,450 | 02-14-2023 |
| $8.325 | $8.33 | $8.325 | $8.37 | $8.32 | 754,410 | 02-13-2023 |
| $8.33 | $8.34 | $8.33 | $8.345 | $8.31 | 1,036,979 | 02-10-2023 |
| $8.33 | $8.38 | $8.33 | $8.39 | $8.31 | 1,718,143 | 02-09-2023 |
| $8.35 | $8.36 | $8.35 | $8.38 | $8.34 | 1,162,544 | 02-08-2023 |
| $8.36 | $8.38 | $8.36 | $8.41 | $8.35 | 2,136,917 | 02-07-2023 |
| $8.38 | $8.39 | $8.38 | $8.41 | $8.36 | 1,049,738 | 02-06-2023 |
News, Short Squeeze, Breakout and More Instantly...
Concert Pharmaceuticals Inc. Company Name:
CNCE Stock Symbol:
NASDAQ Market:
-0.12% G/L:
$8.37 Last:
10,733,298 Volume:
$8.38 Open:
$8.37 Close:
Concert Pharmaceuticals Inc. Website:
Ad
-
Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibit...
-
If all goes according to plan, Concert Pharmaceuticals (NASDAQ: CNCE) will soon cease to be an independent company. The biotech signed a deal to be acquired by a peer; as a result, its share price leaped more than 17% higher on the week, according to data compiled by S&P Global Mark...
-
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma’s Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strength...
Important Investor News Alert (OTC: AVAI)
-
LAS VEGAS, NV / ACCESS Newswire / March 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), tod...